VAXNEUVANCE is a 15-valent pneumococcal conjugate vaccine (PCV) manufactured by Merck Sharp & Dohme Corp. containing S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F. VAXNEUVANCE does not protect against infection and disease caused by Streptococcus pneumoniae strains not present in the vaccine.
VAXNEUVANCE is approved for use in individuals 6 weeks of age and older for the prevention of invasive disease caused by Streptococcus pneumoniae.
VAXNEUVANCE is a 15-valent Pneumococcal Conjugate Vaccine containing Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F individually conjugated to CRM197. Each pneumococcal capsular polysaccharide is activated and individually conjugated to CRM197 carrier protein. Each 0.5 mL dose contains 2.0 mcg of each of Streptococcus pneumoniae polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4.0 mcg of polysaccharide serotype 6B, 30 mcg of CRM197 carrier protein, 1 mg of polysorbate 20, 1.55 mg L-histidine, 4.50 mg sodium chloride, and 125 mcg of aluminum phosphate adjuvant. VAXNEUVANCE does not contain latex.
